{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T12:11:20Z","timestamp":1785845480308,"version":"3.56.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2306802"],"award-info":[{"award-number":["2023YFC2306802"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>About 20% of on-treatment patients with chronic hepatitis B (CHB) experienced low-level viraemia (LLV), which is associated with persistent low-grade inflammation, fibrosis progression, and increased risk of hepatocellular carcinoma. We aimed to investigate the high-risk factors related to LLV.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this retrospective study, patients receiving entecavir (ETV) treatment from January 2018 to January 2023 were enrolled, and were divided into a LLV (HBV DNA 20-2000 IU\/mL) cohort and a complete virological response (CVR) (HBV DNA &amp;lt; 20 IU\/mL) cohort according to the virological response at week 48 posttreatment. Treatment baseline characteristics were retrieved from electronic medical records. Multivariate logistic regression was performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Totally, 1653 patients were enrolled, male patients accounted for 73.0%; the median age was 44 years; the mean HBV DNA level was 5.9 Log<jats:sub>10<\/jats:sub> IU\/ml. Among them, 472 (28.6%) experienced LLV. Multivariate analysis showed that HBeAg positivity (OR = 2.650, 95% CI: 2.000-3.511, <jats:italic>p<\/jats:italic> &amp;lt; 0.001), HBV DNA \u2265 6.0 Log<jats:sub>10<\/jats:sub> IU\/mL (OR = 1.370, 95% CI: 1.054-1.780, <jats:italic>p<\/jats:italic> = 0.019), qHBsAg \u2265 9000 IU\/mL (OR = 4.472, 95% CI: 3.410-5.866, <jats:italic>p<\/jats:italic> &amp;lt; 0.001), cirrhosis (OR = 1.650, 95% CI: 1.234-2.207, <jats:italic>P<\/jats:italic> = 0.001), LSM \u2265 13.0 kPa (OR = 1.644, 95% CI: 1.203-2.246, <jats:italic>p<\/jats:italic> = 0.002), and PLT &amp;lt; 100\u00d710<jats:sup>9<\/jats:sup>\/L (OR = 1.450, 95% CI: 1.094-1.922, <jats:italic>p<\/jats:italic> = 0.010) at baseline were related to the development of LLV.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>High HBV DNA\/HBsAg quantification\/LSM, low PLT, HBeAg positivity, and liver cirrhosis were high-risk factors associated with LLV in patients receiving entecavir treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcimb.2024.1413589","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T06:01:55Z","timestamp":1723010515000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Risk factors related to low-level viraemia in chronic hepatitis B patients receiving entecavir treatment"],"prefix":"10.3389","volume":"14","author":[{"given":"Zhong-Bin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Dan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Fei","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Juan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Xia","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Jie","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengwen","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Yuan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Gao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection","volume":"68","author":"Agarwal","year":"2018","journal-title":"J. Hepatol."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/v9060156","article-title":"The role of cccDNA in HBV maintenance","volume":"9","author":"Allweiss","year":"2017","journal-title":"Viruses"},{"key":"B3","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.2337\/dc12-s064","article-title":"Diagnosis and classification of diabetes mellitus","year":"2012","journal-title":"Diabetes Care."},{"key":"B4","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/jgh.16357","article-title":"Risk factors of low-level viremia in chronic hepatitis B patients receiving Entecavir monotherapy: a retrospective cohort study","volume":"39","author":"Chen","year":"2024","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J. Hepatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL Clinical Practice Guidelines: Drug-induced liver injury","volume":"70","year":"2019","journal-title":"J. Hepatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J. Hepatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jhep.2020.07.032","article-title":"Update of the simplified criteria for autoimmune hepatitis: Evaluation of the methodology for immunoserological testing","volume":"74","author":"Galaski","year":"2021","journal-title":"J. Hepatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1053\/j.gastro.2007.08.025","article-title":"Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B","volume":"133","author":"Gish","year":"2007","journal-title":"Gastroenterology."},{"key":"B10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.cgh.2019.07.010","article-title":"Outcomes of long-term treatment of chronic HBV infection with entecavir or other agents from a randomized trial in 24 countries","volume":"18","author":"Hou","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/j.cgh.2021.01.019","article-title":"Natural history and hepatocellular carcinoma risk in untreated chronic hepatitis B patients with indeterminate phase","volume":"20","author":"Huang","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","article-title":"Hepatitis B","volume":"401","author":"Jeng","year":"2023","journal-title":"Lancet (London England)."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.jhep.2022.07.018","article-title":"Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B","volume":"77","author":"Ji","year":"2022","journal-title":"J. Hepatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1111\/liv.13938","article-title":"The risk of hepatocellular carcinoma within and beyond the first 5 years of entecavir in Korean patients with chronic hepatitis B","volume":"38","author":"Kim","year":"2018","journal-title":"Liver Int."},{"key":"B15","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3350\/cmh.2017.0005","article-title":"Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience","volume":"23","author":"Kim","year":"2017","journal-title":"Clin. Mol. Hepatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/hep.28916","article-title":"Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment","volume":"66","author":"Kim","year":"2017","journal-title":"Hepatology."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/hep.27735","article-title":"Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis","volume":"61","author":"Kim","year":"2015","journal-title":"Hepatol. (Baltimore Md.)."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1111\/jgh.14750","article-title":"Hepatitis B virus DNA levels and overall survival in hepatitis B-related hepatocellular carcinoma patients with low-level viremia","volume":"34","author":"Kim","year":"2019","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1151899","article-title":"Factors associated with persistent positive in HBV DNA level in patients with chronic Hepatitis B receiving entecavir treatment","volume":"13","author":"Li","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1111\/liv.14786","article-title":"Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia","volume":"41","author":"Li","year":"2021","journal-title":"Liver Int."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.655530","article-title":"Efficacy of antiviral treatment in liver biopsy-proven immune-tolerant chronic hepatitis B patients: A retrospective cohort study","volume":"8","author":"Liu","year":"2021","journal-title":"Front. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/hep.28280","article-title":"Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis","volume":"63","author":"Lok","year":"2016","journal-title":"Hepatol. (Baltimore Md.)."},{"key":"B23","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1053\/j.gastro.2012.05.037","article-title":"Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-na\u00efve patients with chronic hepatitis B","volume":"143","author":"Lok","year":"2012","journal-title":"Gastroenterology."},{"key":"B24","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.jhep.2021.05.013","article-title":"Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections","volume":"75","author":"Martinez","year":"2021","journal-title":"J. Hepatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1001\/jama.2018.12086","article-title":"Screening and behavioral counseling interventions to reduce unhealthy alcohol use in adolescents and adults: updated evidence report and systematic review for the US preventive services task force","volume":"320","author":"O'Connor","year":"2018","journal-title":"JAMA."},{"key":"B26","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S2468-1253(19)30119-0","article-title":"A global scientific strategy to cure hepatitis B","volume":"4","author":"Revill","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3350\/kjhep.2011.17.4.268","article-title":"Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B","volume":"17","author":"Song","year":"2011","journal-title":"Korean J. Hepatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1016\/j.cgh.2020.03.001","article-title":"Persistent low level of hepatitis B virus promotes fibrosis progression during therapy","volume":"18","author":"Sun","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatol. (Baltimore Md.)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/jmv.25644","article-title":"Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate","volume":"92","author":"Uchida","year":"2020","journal-title":"J. Med. Virol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41533-016-0004-8","article-title":"National guidelines for smoking cessation in primary care: a literature review and evidence analysis","volume":"27","author":"Verbiest","year":"2017","journal-title":"NPJ Primary Care Respir. Med."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1121778","article-title":"Serum cytokine change profile associated with HBsAg loss during combination therapy with PEG-IFN-\u03b1 in NAs-suppressed chronic hepatitis B patients","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"S878","DOI":"10.1016\/S0168-8278(22)02049-9","article-title":"Low-level viremia in patients with chronic hepatitis B receiving entecavir, tenofovir and tenofovir alafenamide","volume":"77","author":"Wang","year":"2022","journal-title":"J. Hepatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur. Heart J."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jhep.2021.11.024","article-title":"How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development","volume":"76","author":"Wong","year":"2022","journal-title":"J. Hepatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1111\/j.1365-2036.2012.05098.x","article-title":"Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years","volume":"35","author":"Wong","year":"2012","journal-title":"Alimentary Pharmacol. Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"666","DOI":"10.3748\/wjg.v27.i8.666","article-title":"New therapeutic options for persistent low-level viremia in patients with chronic hepatitis B virus infection: Increase of entecavir dosage","volume":"27","author":"Yin","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/ajg.2011.45","article-title":"Three years of continuous entecavir therapy in treatment-na\u00efve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety","volume":"106","author":"Yuen","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1097\/CM9.0000000000001793","article-title":"Low-level viremia in nucleoside analog-treated chronic hepatitis B patients","volume":"134","author":"Zhang","year":"2021","journal-title":"Chin. Med. J."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2024.1413589\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T06:02:01Z","timestamp":1723010521000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2024.1413589\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,7]]},"references-count":39,"alternative-id":["10.3389\/fcimb.2024.1413589"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2024.1413589","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,7]]},"article-number":"1413589"}}